Understanding why some people develop autoimmune or lung diseases while others with similar exposures do not has long been one of immunology's central puzzles. A key part of the answer may lie not in circulating blood cells — the traditional focus of genetic risk studies — but in the specialized immune cells permanently stationed within lung tissue itself. This distinction matters because treatments targeting systemic immunity may miss the actual cells where disease-driving variants exert their effects.
Published in Nature Immunology, this study applied single-cell expression quantitative trait locus (eQTL) analysis across 29 distinct immune cell subsets isolated directly from human lung tissue. By integrating these cell-type-specific eQTL maps with genome-wide association study (GWAS) data spanning lung diseases, autoimmune conditions, and infectious diseases, the researchers identified which genetic variants alter gene expression in which specific resident immune populations. A notable convergence emerged around ZFP57 — a transcriptional regulator with epigenetic functions — whose eQTL signal colocalized with GWAS signals from multiple both systemic and organ-restricted autoimmune diseases, suggesting it operates through shared upstream genetic circuitry across conditions that clinically appear quite different.
This work represents a meaningful methodological advance over prior eQTL studies, which typically relied on peripheral blood mononuclear cells and thus missed tissue-specific regulatory architecture entirely. The resolution to 29 cell subtypes is substantially finer than most earlier efforts. That said, critical limitations apply: eQTL analysis is observational and cannot establish causality; the direction of effect — whether variants cause disease by altering ZFP57 and related genes or merely correlate — remains unresolved. The cohort size and demographic composition of lung tissue donors will also constrain generalizability. Still, the publicly released lung immune database accompanying this paper (lung.dice-database.org) could meaningfully accelerate target discovery for both autoimmune therapeutics and infectious disease vulnerability research.